NWBO (Northwest Biotherapeutics) Research & Development: $25.29 Mil (TTM As of Mar. 2026)


NWBO Northwest Biotherapeutics Inc NWBO
17 GF Score
Price $0.19
! 5 Warning Signs
View Full Analysis

What is Northwest Biotherapeutics Research & Development?

Northwest Biotherapeutics NWBO -0.58% 17 Research & Development is $25.29 Mil as of Mar. 2026. GuruFocus rates NWBO with a GF Score™ of 17/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Northwest Biotherapeutics's Research & Development for the three months ended in Mar. 2026 was $4.86 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $25.29 Mil.

Northwest Biotherapeutics  (OTCPK:NWBO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Northwest Biotherapeutics Research & Development Related Terms

Northwest Biotherapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Northwest Biotherapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Northwest Biotherapeutics Research & Development Chart

Northwest Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.31 35.51 27.73 34.89 28.79

Northwest Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.35 7.43 7.45 5.55 4.86
NWBO
17GF Score
Northwest Biotherapeutics Inc NWBO
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Northwest Biotherapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $25.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $25.29 Mil mean?
Northwest Biotherapeutics (NWBO) has a Research & Development of $25.29 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Northwest Biotherapeutics and its competitors.
Is Northwest Biotherapeutics' Research & Development too high?
Northwest Biotherapeutics' current Research & Development is $25.29 Mil. Overall, Northwest Biotherapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Research & Development compare to PROK and AVIR?
Northwest Biotherapeutics' Research & Development of $25.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Northwest Biotherapeutics and its competitors. Northwest Biotherapeutics's current Research & Development is $25.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Northwest Biotherapeutics (NWBO) has a current Research & Development of $25.29 Mil. The current Research & Development is $25.29 Mil. Northwest Biotherapeutics' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Northwest Biotherapeutics (NWBO), the current Research & Development is $25.29 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Northwest Biotherapeutics Business Description

Other Exchanges NBYB:Germany
Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
17GF Score

Get the complete analysis for NWBO

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price